{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:13Z","timestamp":1757618113988,"version":"3.44.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01150-8","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T08:53:42Z","timestamp":1747385622000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-994X","authenticated-orcid":false,"given":"Tomas","family":"Buchler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187\u201396.","journal-title":"N Engl J Med"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2021.39.6_suppl.106","volume":"39","author":"DJ George","year":"2021","unstructured":"George DJ, Shore ND, Saad F, Cookson M, Saltzstein D, Tutrone RF, et al. Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: subgroup analysis from the phase III HERO study. J Clin Oncol. 2021;39:106.","journal-title":"J Clin Oncol"},{"key":"1150_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40265-023-01894-5","volume":"83","author":"M Shirley","year":"2023","unstructured":"Shirley M. Relugolix: a review in advanced prostate cancer. Drugs. 2023;83:59\u201368.","journal-title":"Drugs"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2023.41.6_suppl.74","volume":"41","author":"RR McKay","year":"2023","unstructured":"McKay RR, Gandhi R, Yang E, Pruett J, Nwokeji E, Fallick M. Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): analysis from a US EMR database. J Clin Oncol. 2023;41:74.","journal-title":"J Clin Oncol"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/oncolo\/oyad036","volume":"28","author":"S Kasparian","year":"2023","unstructured":"Kasparian S, Wei O, Tsai N-C, Palmer J, Pal S, Lyou Y, et al. A practical guide to relugolix: early experience with oral androgen deprivation therapy. Oncologist. 2023;28:699\u2013705.","journal-title":"Oncologist"},{"key":"1150_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/cpt.2743","volume":"113","author":"TY Lee","year":"2023","unstructured":"Lee TY, Pierrillas PB, Lin YW, de Greef R, Zandvliet AS, Schindler E, et al. Population PK and semimechanistic PK\/PD modeling and simulation of relugolix effects on testosterone suppression in men with prostate cancer. Clin Pharmacol Ther. 2023;113:124\u201334.","journal-title":"Clin Pharmacol Ther"},{"key":"1150_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.874973","author":"L Xing","year":"2022","unstructured":"Xing L, Liu YN, Yao H, Wang T, Xie F, Luo S, et al. An efficient UPLC-MS\/MS method established to detect relugolix concentration in rat plasma. Front Pharmacol. 2022:13:874973.","journal-title":"Front Pharmacol"},{"key":"1150_CR8","first-page":"773","volume":"61","author":"T Bohnert","year":"2022","unstructured":"Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Pekcec A, et al. Effects of androgen receptor inhibitors on drug transporters and implications for drug\u2013drug interactions in prostate cancer treatment. Clin Pharmacokinet. 2022;61:773\u201388.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","volume":"55","author":"AH Schinkel","year":"2003","unstructured":"Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP-binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55:3\u201329.","journal-title":"Adv Drug Deliv Rev"},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-020-00881-3","volume":"59","author":"A Van den Bergh","year":"2020","unstructured":"Van den Bergh A, Snoeys J, De Zwart L, Ward P, Lopez-Gitlitz A, Ouellet D, et al. Pharmacokinetic drug-drug interaction of apalutamide, part 2: investigating interaction potential using a physiologically based pharmacokinetic model. Clin Pharmacokinet. 2020;59:1149\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1124\/dmd.118.084517","volume":"47","author":"R de Vries","year":"2019","unstructured":"de Vries R, Jacobs F, Mannens G, Snoeys J, Cuyckens F, Chien C, et al. Apalutamide absorption, metabolism, and excretion in healthy men, and enzyme reaction in human hepatocytes. Drug Metab Dispos. 2019;47:453\u201364.","journal-title":"Drug Metab Dispos"},{"key":"1150_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40262-019-00808-7","volume":"59","author":"C P\u00e9rez-Ruixo","year":"2020","unstructured":"P\u00e9rez-Ruixo C, P\u00e9rez-Blanco JS, Chien C, Yu M, Ouellet D, P\u00e9rez-Ruixo JJ, et al. Population pharmacokinetics of apalutamide and its active metabolite N-desmethyl-apalutamide in healthy and castration-resistant prostate cancer subjects. Clin Pharmacokinet. 2020;59:229\u201344.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","volume":"59","author":"I Duran","year":"2020","unstructured":"Duran I, Carles J, Bulat I, Hellemans P, Mitselos A, Ward P, et al. Pharmacokinetic drug-drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer. Clin Pharmacokinet. 2020;59:1135\u201348.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR14","unstructured":"Companies JP. ERLEADA (apalutamide) [Prescribing Information]. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210951s004lbl.pdf."},{"key":"1150_CR15","first-page":"492","volume":"10","author":"JA Gibbons","year":"2021","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Othman AA, Mordenti J, Palmisano J. Pharmacokinetic drug interactions of apalutamide with CYP3A, CYP2C8, P-glycoprotein, and BCRP substrates. Clin Pharmacol Drug Dev. 2021;10:492\u2013503.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1150_CR16","unstructured":"Myovant Sciences I. ORGOVYX (relugolix) [Prescribing Information]. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214621s000lbl.pdf."},{"key":"1150_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11523-023-00967-5","volume":"18","author":"J De La Cerda","year":"2023","unstructured":"De La Cerda J, Dunshee C, Gervasi L, Sieber P, Belkoff L, Tutrone R, et al. A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced prostate cancer. Target Oncol. 2023;18:383\u201390.","journal-title":"Target Oncol"},{"key":"1150_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01139-3","author":"J De La Cerda","year":"2025","unstructured":"De La Cerda J, Belkoff L, Courtney KD, Diamond E, D\u2019Olimpio J, Dunshee C, et al. Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: data from a 52-week clinical trial. Target Oncol. 2025. https:\/\/doi.org\/10.1007\/s11523-025-01139-3.","journal-title":"Target Oncol"},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11523-022-00932-8","volume":"18","author":"G Brown","year":"2023","unstructured":"Brown G, Belkoff L, Hafron JM, Saltzstein DR, Potdar R, Bhaumik A, et al. Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases. Target Oncol. 2023;18:95\u2013103.","journal-title":"Target Oncol"},{"key":"1150_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54:1057\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt J-S, Beddo V, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54:1043\u201355.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR22","unstructured":"Administration USF and D. Clinical pharmacology and biopharmaceutics review: enzalutamide (NDA 203415). Silver Spring, MD; 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf."},{"key":"1150_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clgc.2019.05.020","volume":"18","author":"ML Joulia","year":"2020","unstructured":"Joulia ML, Carton E, Jouinot A, Allard M, Huillard O, Khoudour N, et al. Pharmacokinetic\/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2020;18:155\u201360.","journal-title":"Clin Genitourin Cancer"},{"key":"1150_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1078-0432.CCR-17-2336","volume":"24","author":"BP Belderbos","year":"2018","unstructured":"Belderbos BP, Bins S, van Leeuwen RW, Oomen-de Hoop E, van der Meer N, de Bruijn P, et al. Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug\u2013drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) Patients. Clin Cancer Res. 2018;24:541\u20136.","journal-title":"Clin Cancer Res"},{"key":"1150_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10928-023-09867-7","volume":"50","author":"Y Otsuka","year":"2023","unstructured":"Otsuka Y, Poondru S, Bonate PL, Rose RH, Jamei M, Ushigome F, et al. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. J Pharmacokinet Pharmacodyn. 2023;50:365\u201376.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1150_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40262-023-01255-1","volume":"62","author":"SEH Detert Oude Weme","year":"2023","unstructured":"Detert Oude Weme SEH, Hulskotte LMG, Vervenne WL, Imholz ALT, Cremers RGHM, Taxis K, et al. Enzalutamide reduces oxycodone exposure in men with prostate cancer. Clin Pharmacokinet. 2023;62:989\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/bdd.2103","volume":"38","author":"J Weiss","year":"2017","unstructured":"Weiss J, Kocher J, Mueller C, Rosenzweig S, Theile D. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharm Drug Dispos. 2017;38:517\u201325.","journal-title":"Biopharm Drug Dispos"},{"key":"1150_CR28","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/cts.13637","volume":"16","author":"L Zhang","year":"2023","unstructured":"Zhang L, Tang J, He L, et al. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates. Clin Transl Sci. 2023;16:1531\u201342.","journal-title":"Clin Transl Sci"},{"key":"1150_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.clgc.2023.03.009","volume":"21","author":"DJ George","year":"2023","unstructured":"George DJ, Saad F, Cookson MS, et al. Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 2023;21:383\u201392.","journal-title":"Clin Genitourin Cancer"},{"key":"1150_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature17954","volume":"533","author":"Z Li","year":"2016","unstructured":"Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, et al. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016;533:547\u201351.","journal-title":"Nature"},{"key":"1150_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jchromb.2018.12.003","volume":"1104","author":"P Caron","year":"2019","unstructured":"Caron P, Turcotte V, L\u00e9vesque E, Guillemette C. An LC-MS\/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5\u03b1-abiraterone, and their inactive glucuronide derivatives. J Chromatogr B, Anal Technol Biomed life Sci. 2019;1104:249\u201355.","journal-title":"J Chromatogr B, Anal Technol Biomed life Sci"},{"key":"1150_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1124\/dmd.119.088229","volume":"48","author":"J Vaillancourt","year":"2020","unstructured":"Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, et al. Glucuronidation of abiraterone and its pharmacologically active metabolites by UGT1A4, influence of polymorphic variants and their potential as inhibitors of steroid glucuronidation. Drug Metab Dispos. 2020;48:75\u201384.","journal-title":"Drug Metab Dispos"},{"key":"1150_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.890323","volume":"12","author":"A Keranmu","year":"2022","unstructured":"Keranmu A, Yang F-Y, Wahafu W, Han S-J, Yang G-S, Xing N-Z. Biotransformation of abiraterone into five characteristic metabolites by the rat gut microbiota and liver microsomes. Front Oncol. 2022;12: 890323.","journal-title":"Front Oncol"},{"key":"1150_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsbmb.2013.10.027","volume":"144 Pt A","author":"S Deb","year":"2014","unstructured":"Deb S, Chin MY, Adomat H, Guns EST. Abiraterone inhibits 1\u03b1,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro. J Steroid Biochem Mol Biol. 2014;144 Pt A:50\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1150_CR35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1124\/dmd.116.070672","volume":"44","author":"J Monbaliu","year":"2016","unstructured":"Monbaliu J, Gonzalez M, Bernard A, Jiao J, Sensenhauser C, Snoeys J, et al. In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity. Drug Metab Dispos. 2016;44:1682\u201391.","journal-title":"Drug Metab Dispos"},{"key":"1150_CR36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1158\/1078-0432.557.11.2","volume":"11","author":"MR Acharya","year":"2005","unstructured":"Acharya MR, Venitz J, Figg WD. Chemotherapy and transporter-mediated alterations in pharmacokinetics: implications for drug development. Clin Cancer Res. 2005;11:557\u201364.","journal-title":"Clin Cancer Res"},{"key":"1150_CR37","doi-asserted-by":"publisher","first-page":"A1618","DOI":"10.1161\/circ.142.suppl_3.16180","volume":"142","author":"B Shrestha","year":"2020","unstructured":"Shrestha B, Gouli S, Shrestha A. Cardiovascular adverse events associated with androgen receptor-targeted therapy used in the treatment of prostate cancer. Circulation. 2020;142:A1618.","journal-title":"Circulation"},{"key":"1150_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1200\/JCO.2024.42.4_suppl.85","volume":"42","author":"J Guan","year":"2024","unstructured":"Guan J, Adroja S, Ajmal Z, Gao Y, Spetsieris N, Hu S, et al. Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer. J Clin Oncol. 2024;42:85.","journal-title":"J Clin Oncol"},{"key":"1150_CR39","first-page":"291","volume":"6","author":"J Goh","year":"2023","unstructured":"Goh J, West J, Angelergues A, Kotwal S, Aggarwal R, Tombal B, et al. Drug-drug interactions with androgen receptor inhibitors for prostate cancer: considerations for clinical practice. Eur Urol Oncol. 2023;6:291\u2013304.","journal-title":"Eur Urol Oncol."},{"key":"1150_CR40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40262-019-00827-4","volume":"59","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Massard C, Bono J, Jones R, Garcia J, Nakabayashi M, et al. Pharmacokinetics and safety of darolutamide in patients with prostate cancer: results from preclinical and clinical studies. Clin Pharmacokinet. 2020;59:501\u201312.","journal-title":"Clin Pharmacokinet"},{"key":"1150_CR41","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2022.40.28_suppl.403","volume":"40","author":"N Shore","year":"2022","unstructured":"Shore N, Chowdhury S, Hadaschik BA, Matsubara N, Armstrong AJ, Higano CS, et al. Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer: final analysis of the phase III ARAMIS trial. J Clin Oncol. 2022;40:1310\u20136.","journal-title":"J Clin Oncol"},{"key":"1150_CR42","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamaoncol.2023.7279","volume":"10","author":"DE Spratt","year":"2024","unstructured":"Spratt DE, George DJ, Shore ND, Cookson MS, Saltzstein DR, Tutrone R, et al. Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA Oncol. 2024;10:594\u2013602.","journal-title":"JAMA Oncol"},{"key":"1150_CR43","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.euo.2023.11.024","volume":"7","author":"R Tutrone","year":"2024","unstructured":"Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, et al. Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: results from the phase 3 HERO study. Eur Urol Oncol. 2024;7:906\u201313.","journal-title":"Eur Urol Oncol."},{"key":"1150_CR44","unstructured":"FDA US. Lynparza (Olaparib) Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s011lbl.pdf."},{"key":"1150_CR45","unstructured":"FDA US. Rubraca (Rucaparib) Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209115s005lbl.pdf."},{"key":"1150_CR46","unstructured":"FDA US. Zejula (Niraparib) Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208447s008lbl.pdf."},{"key":"1150_CR47","unstructured":"FDA US. Talzenna (Talazoparib) Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/211651s005lbl.pdf."},{"key":"1150_CR48","unstructured":"ClinicalTrials.gov. U.S. National Library of Medicine; 2025. https:\/\/clinicaltrials.gov\/."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01150-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:51:57Z","timestamp":1757170317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01150-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01150-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"24 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access publishing supported by the institutions participating in the CzechELib Transformative Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tomas Buchler: Research support from AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck KGaA, MSD, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi\/Aventis; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol-Myers Squibb, AstraZeneca, Roche, Servier, Accord, MSD, and Pfizer. All unrelated to the present paper. Tomas Buchler is an Editorial Board member of Targeted Oncology. Tomas Buchler was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Review design, first draft, editing: Buchler.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship declaration"}}]}}